Most health research in the UK is paid for by government research councils, the NHS, large medical charities or commercial companies. Each has its own priorities, and each has more applications than money.
Commercial funding follows a commercial return. If a condition affects very few people, or if the question is about making an existing medicine safer rather than selling a new one, the business case is weak even when the human case is strong.
Public funders tend to favour larger studies with established teams. Small, practical projects — a pilot test, a better patient leaflet, a training programme — often score badly even when they would help people quickly.
That gap is where Duet works. We look for projects that are useful, deliverable and unlikely to be funded elsewhere, and we back them with money and with hands-on experience.
If something here worries you
This is general information. For advice about your own health or medicines, speak to your GP or pharmacist.
More plain-English guides
NSAIDs: the everyday painkillers with a serious safety problem
Ibuprofen, naproxen and aspirin are on supermarket shelves everywhere. Among hospital admissions that are due to adverse drug reactions, about 30% are attributed to NSAIDs.
Rare eye diseases: how a second opinion saved our Founder's sight
Salzmann Nodular Degeneration is relatively simple to diagnose and relatively simple to treat — but it is often not looked for at all. One of Duet's Founders found that out the hard way.
What is a rare disease?
A plain-English explanation of what makes a condition rare, why diagnosis often takes so long, and what to ask your doctor.